Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raises the price target from $32 to $33.
August 15, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Peter Lawson maintains an Overweight rating on Syndax Pharmaceuticals and raises the price target from $32 to $33.
The Overweight rating and increased price target from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive short-term price appreciation for Syndax Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100